{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:43:04Z","timestamp":1792233784055,"version":"4.4.0"},"publisher-location":"Cham","reference-count":158,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030340247","type":"print"},{"value":"9783030340254","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-34025-4_11","type":"book-chapter","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T17:03:24Z","timestamp":1583341404000},"page":"203-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Melanoma Metabolism: Cell Survival and Resistance to Therapy"],"prefix":"10.1007","author":[{"given":"Rafael","family":"Lu\u00eds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheila","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","volume":"21","author":"C Abildgaard","year":"2015","unstructured":"Abildgaard C, Guldberg P (2015) Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med 21:164\u2013171. https:\/\/doi.org\/10.1016\/j.molmed.2014.12.007","journal-title":"Trends Mol Med"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4626-9","volume":"18","author":"A Aiderus","year":"2018","unstructured":"Aiderus A, Black MA, Dunbier AK (2018) Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. BMC Cancer 18:1\u201315. https:\/\/doi.org\/10.1186\/s12885-018-4626-9","journal-title":"BMC Cancer"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.4049\/jimmunol.168.10.5070","volume":"168","author":"ML Alegre","year":"2000","unstructured":"Alegre ML, Frauwirth KA, Thompson CB et al (2000) Inhibition of CTLA-4 function by the regulatory subunit of serine\/threonine phosphatase 2A. J Immunol 168:5070\u20135078. https:\/\/doi.org\/10.4049\/jimmunol.168.10.5070","journal-title":"J Immunol"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","volume":"11","author":"Z Ali","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J (2013) Melanoma epidemiology, biology and prognosis. Eur J Cancer Suppl 11:81\u201391. https:\/\/doi.org\/10.1016\/j.ejcsup.2013.07.012","journal-title":"Eur J Cancer Suppl"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3","journal-title":"Lancet"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12964-018-0297-z","volume":"16","author":"E Andreucci","year":"2018","unstructured":"Andreucci E, Pietrobono S, Peppicelli S et al (2018) SOX2 as a novel contributor of oxidative metabolism in melanoma cells. Cell Commun Signal 16:87. https:\/\/doi.org\/10.1186\/s12964-018-0297-z","journal-title":"Cell Commun Signal"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/583748","volume":"2010","author":"B Bandarchi","year":"2010","unstructured":"Bandarchi B, Ma L, Navab R et al (2010) From melanocyte to metastatic malignant melanoma. Dermatol Res Pract 2010:1\u20138. https:\/\/doi.org\/10.1155\/2010\/583748","journal-title":"Dermatol Res Pract"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.18632\/oncotarget.13832","volume":"8","author":"RA Bartolom\u00e9","year":"2017","unstructured":"Bartolom\u00e9 RA, Torres S, de Val SI et al (2017) VE-cadherin RGD motifs promote metastasis and constitute a potential therapeutic target in melanoma and breast cancers. Oncotarget 8:215\u2013227. https:\/\/doi.org\/10.18632\/oncotarget.13832","journal-title":"Oncotarget"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","volume":"9","author":"BC Bastian","year":"2014","unstructured":"Bastian BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239\u2013271. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104658","journal-title":"Annu Rev Pathol"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-013-0025-9","volume":"14","author":"M Batus","year":"2013","unstructured":"Batus M, Waheed S, Ruby C et al (2013) Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol 14:179\u2013194. https:\/\/doi.org\/10.1007\/s40257-013-0025-9","journal-title":"Am J Clin Dermatol"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1093\/emboj\/cdg245","volume":"22","author":"C Brakebusch","year":"2003","unstructured":"Brakebusch C (2003) The integrin-actin connection, an eternal love affair. EMBO J 22:2324\u20132333. https:\/\/doi.org\/10.1093\/emboj\/cdg245","journal-title":"EMBO J"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.4161\/cc.8.12.8745","volume":"8","author":"JR Brody","year":"2009","unstructured":"Brody JR, Costantino CL, Berger AC et al (2009) Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8:1930\u20131934. https:\/\/doi.org\/10.4161\/cc.8.12.8745","journal-title":"Cell Cycle"},{"key":"11_CR14","doi-asserted-by":"publisher","unstructured":"Buri\u00e1n Z, Lad\u00e1nyi A, Barbai T et al (2019) Selective inhibition of HIF1\u03b1 expression by ZnSO4 has antitumoral effects in human melanoma. Pathol Oncol Res. https:\/\/doi.org\/10.1007\/s12253-018-00573-1","DOI":"10.1007\/s12253-018-00573-1"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0667-y","volume":"16","author":"G Cesi","year":"2017","unstructured":"Cesi G, Walbrecq G, Zimmer A et al (2017) ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer 16:1\u201316. https:\/\/doi.org\/10.1186\/s12943-017-0667-y","journal-title":"Mol Cancer"},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2016.07.004","volume":"30","author":"YC Chae","year":"2016","unstructured":"Chae YC, Vaira V, Caino MC et al (2016) Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell 30:257\u2013272. https:\/\/doi.org\/10.1016\/j.ccell.2016.07.004","journal-title":"Cancer Cell"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C Chang","year":"2015","unstructured":"Chang C, Qiu J, Sullivan DO et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229\u20131241. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016. Metabolic","journal-title":"Cell"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","volume":"20","author":"T Chodon","year":"2014","unstructured":"Chodon T, Comin-Anduix B, Chmielowski B et al (2014) Adoptive transfer of MART-1 T cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457\u20132465. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3017","journal-title":"Clin Cancer Res"},{"key":"11_CR19","doi-asserted-by":"publisher","unstructured":"Cichorek M, Wachulska M, Stasiewicz A, Tymi\u0144ska A (2013) Skin melanocytes: biology and development. Postep Dermatologii i Alergol:30:30\u201330:41. https:\/\/doi.org\/10.5114\/pdia.2013.33376","DOI":"10.5114\/pdia.2013.33376"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.18632\/oncotarget.1420","volume":"4","author":"P Corazao-Rozas","year":"2013","unstructured":"Corazao-Rozas P, Guerreschi P, Jendoubi M et al (2013) Mitochondrial oxidative stress is the achille\u2019s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget 4:1986\u20131998. https:\/\/doi.org\/10.18632\/oncotarget.1420","journal-title":"Oncotarget"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.biochi.2018.03.006","volume":"155","author":"N Couto","year":"2018","unstructured":"Couto N, Caja S, Maia J et\u00a0al (2018) Exosomes as emerging players in cancer biology. Biochimie 155:2\u201310. https:\/\/doi.org\/10.1016\/j.biochi.2018.03.006","journal-title":"Biochimie"},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Cs\u00f3ka","year":"2012","unstructured":"Cs\u00f3ka B, Selmeczy Z, Koscs\u00f3 B et al (2012) Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 26:376\u2013386. https:\/\/doi.org\/10.1096\/fj.11-190934","journal-title":"FASEB J"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","volume":"23","author":"DL Dai","year":"2005","unstructured":"Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473\u20131482. https:\/\/doi.org\/10.1200\/JCO.2005.07.168","journal-title":"J Clin Oncol"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","volume":"15","author":"CV Dang","year":"2009","unstructured":"Dang CV, Le A, Gao P (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15:6479\u20136483. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0889","journal-title":"Clin Cancer Res"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1083\/jcb.200208050","volume":"159","author":"SP Denker","year":"2002","unstructured":"Denker SP, Barber DL (2002) Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol 159:1087\u20131096. https:\/\/doi.org\/10.1083\/jcb.200208050","journal-title":"J Cell Biol"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molonc.2015.08.003","volume":"10","author":"N Dhomen","year":"2015","unstructured":"Dhomen N, Baenke F, Galbraith L et al (2015) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol 10:73\u201384. https:\/\/doi.org\/10.1016\/j.molonc.2015.08.003","journal-title":"Mol Oncol"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/itt.s134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes J, Soares P, Populo H (2018) Melanoma treatment in review. ImmunoTargets Ther 7:35\u201349. https:\/\/doi.org\/10.2147\/itt.s134842","journal-title":"ImmunoTargets Ther"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F (2018) Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol 9:14. https:\/\/doi.org\/10.3389\/fimmu.2018.00014","journal-title":"Front Immunol"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers9100140","volume":"9","author":"A Emmanouilidi","year":"2017","unstructured":"Emmanouilidi A, Falasca M (2017) Targeting PDK1 for chemosensitization of cancer cells. Cancers (Basel) 9:1\u201325. https:\/\/doi.org\/10.3390\/cancers9100140","journal-title":"Cancers (Basel)"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8:48\u201356. https:\/\/doi.org\/10.1177\/1758834015616934","journal-title":"Ther Adv Med Oncol"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/pcmr.12661","volume":"31","author":"GM Fischer","year":"2019","unstructured":"Fischer GM, Gopal YNV, Mcquade JL et al (2019) Metabolic strategies of melanoma cells: mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res 31:713\u2013745. https:\/\/doi.org\/10.1111\/pcmr.12661. Metabolic","journal-title":"Pigment Cell Melanoma Res"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/cts.12551","volume":"11","author":"P Fisel","year":"2018","unstructured":"Fisel P, Schaeffeler E, Schwab M (2018) Clinical and functional relevance of the Monocarboxylate transporter family in disease pathophysiology and drug therapy. Clin Transl Sci 11:352\u2013364. https:\/\/doi.org\/10.1111\/cts.12551","journal-title":"Clin Transl Sci"},{"key":"11_CR35","first-page":"527","volume":"53","author":"BB Fredholm","year":"2001","unstructured":"Fredholm BB, IJzerman AP, Jacobson KA et al (2001) International Union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527\u2013552","journal-title":"Pharmacol Rev"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrc1075","volume":"3","author":"P Friedl","year":"2003","unstructured":"Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362\u2013374. https:\/\/doi.org\/10.1038\/nrc1075","journal-title":"Nat Rev Cancer"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4137\/ijtr.s4157","volume":"3","author":"D Fuchs","year":"2011","unstructured":"Fuchs D, Margreiter R, Brandacher G et al (2011) IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res 3:113\u2013120. https:\/\/doi.org\/10.4137\/ijtr.s4157","journal-title":"Int J Tryptophan Res"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/exd.13417","volume":"27","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kakizaki A, Kambayashi Y et al (2018) Cytotoxic anti-melanoma drugs suppress the activation of M2 macrophages. Exp Dermatol 27:64\u201370. https:\/\/doi.org\/10.1111\/exd.13417","journal-title":"Exp Dermatol"},{"key":"11_CR39","volume-title":"Tumor-induced immune suppresion\u00a0\u2013 mechanisms and therapeutic reversal","year":"2014","unstructured":"Gabrilovich DI, Hurwitz AA (eds) (2014) Tumor-induced immune suppresion\u00a0\u2013 mechanisms and therapeutic reversal, 2nd edn. Springer, New York","edition":"2"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069.Loss","volume":"167","author":"J Gao","year":"2017","unstructured":"Gao J, Shi LZ, Zhao H et al (2017) Loss of IFN\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397\u2013404. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069.Loss","journal-title":"Cell"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","volume":"27","author":"C Garbe","year":"2009","unstructured":"Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3\u20139. https:\/\/doi.org\/10.1016\/j.clindermatol.2008.09.001","journal-title":"Clin Dermatol"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1073\/pnas.1219603110","volume":"110","author":"B Garmy-Susini","year":"2013","unstructured":"Garmy-Susini B, Avraamides CJ, Desgrosellier JS et al (2013) PI3K\u03b1 activates integrin \u03b14\u03b21 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci 110:9042\u20139047. https:\/\/doi.org\/10.1073\/pnas.1219603110","journal-title":"Proc Natl Acad Sci"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1172\/JCI76012","volume":"125","author":"VA Gerriets","year":"2015","unstructured":"Gerriets VA, Kishton RJ, Nichols AG et al (2015) Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest 125:194\u2013207. https:\/\/doi.org\/10.1172\/JCI76012","journal-title":"J Clin Invest"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/ni.3577","volume":"17","author":"VA Gerriets","year":"2016","unstructured":"Gerriets VA, Kishton RJ, Johnson MO et al (2016) Foxp3 and toll-like receptor signaling balance T reg cell anabolic metabolism for suppression. Nat Immunol 17:1459\u20131466. https:\/\/doi.org\/10.1038\/ni.3577","journal-title":"Nat Immunol"},{"key":"11_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cncr.22427","volume":"109","author":"HJ Gogas","year":"2007","unstructured":"Gogas HJ, Kirkwood JM, Sondak VK (2007) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455\u2013464. https:\/\/doi.org\/10.1002\/cncr.22427","journal-title":"Cancer"},{"key":"11_CR46","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1158\/1055-9965.EPI-12-1346","volume":"22","author":"AM Goldstein","year":"2013","unstructured":"Goldstein AM, Tucker MA (2013) Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers 22:528\u2013532. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1346","journal-title":"Cancer Epidemiol Biomarkers"},{"key":"11_CR47","doi-asserted-by":"publisher","first-page":"78174","DOI":"10.18632\/oncotarget.19836","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Scotto D, Josephs DH et al (2017) BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget 8:78174\u201378192. https:\/\/doi.org\/10.18632\/oncotarget.19836","journal-title":"Oncotarget"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.cmr.0000124207.72344.38","volume":"14","author":"B Guillot","year":"2001","unstructured":"Guillot B, Dalac S, Delaunay M et al (2001) Cutaneous malignant melanoma and neurofibromatosis type 1. Melanoma Res 14:159\u2013163. https:\/\/doi.org\/10.1097\/01.cmr.0000124207.72344.38","journal-title":"Melanoma Res"},{"key":"11_CR49","first-page":"591","volume":"64","author":"GP Guy","year":"2015","unstructured":"Guy GP, Thomas CC, Thompson T et al (2015) Vital signs: melanoma incidence and mortality trends and projections\u00a0\u2013 United States, 1982-2030. MMWR Morb Mortal Wkly Rep 64:591\u2013596","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1200\/JCO.2010.32.6223","volume":"29","author":"R Haq","year":"2011","unstructured":"Haq R, Fisher DE (2011) Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 29:3474\u20133482. https:\/\/doi.org\/10.1200\/JCO.2010.32.6223","journal-title":"J Clin Oncol"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq R, Shoag J, Andreu-Perez P et al (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF. Cancer Cell 23:302\u2013315. https:\/\/doi.org\/10.1016\/j.ccr.2013.02.003","journal-title":"Cancer Cell"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"key":"11_CR53","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","volume":"17","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Siepmann T, Engel J et\u00a0al (2017) Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer 17:536. https:\/\/doi.org\/10.1186\/s12885-017-3529-5","journal-title":"BMC Cancer"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150:251\u2013263. https:\/\/doi.org\/10.1016\/j.cell.2012.06.024","journal-title":"Cell"},{"key":"11_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","volume":"115","author":"UB Hofmann","year":"2000","unstructured":"Hofmann UB, Westphal JR, Van Muijen GNP, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337\u2013344. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00068.x","journal-title":"J Invest Dermatol"},{"key":"11_CR56","doi-asserted-by":"publisher","unstructured":"Holness MJ, Sugden MC (2003) Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans:1143\u20131151. https:\/\/doi.org\/10.1042\/bst0311143","DOI":"10.1042\/bst0311143"},{"key":"11_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.abb.2014.07.019.The","volume":"563","author":"JJ Hsiao","year":"2015","unstructured":"Hsiao JJ, Fisher DE (2015) The roles of Microphthalmia transcription factor and pigmentation in melanoma. Arch Biochem Biophys 563:28\u201334. https:\/\/doi.org\/10.1016\/j.abb.2014.07.019.The","journal-title":"Arch Biochem Biophys"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-0763-x","volume":"37","author":"R Huang","year":"2018","unstructured":"Huang R, Rofstad EK (2018) Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res 37:1\u201314. https:\/\/doi.org\/10.1186\/s13046-018-0763-x","journal-title":"J Exp Clin Cancer Res"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/modpathol.2011.5.IL-10","volume":"24","author":"E Itakura","year":"2011","unstructured":"Itakura E, Huang R, Wen D et al (2011) IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 24:801\u2013809. https:\/\/doi.org\/10.1038\/modpathol.2011.5.IL-10","journal-title":"Mod Pathol"},{"key":"11_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535\u2013546. https:\/\/doi.org\/10.1182\/blood-2009-03-211714","journal-title":"Blood"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT et al (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214:895\u2013904. https:\/\/doi.org\/10.1084\/jem.20160801","journal-title":"J Exp Med"},{"key":"11_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1047584","volume":"4","author":"A Kakizaki","year":"2015","unstructured":"Kakizaki A, Fujimura T, Furudate S et al (2015) Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. Oncoimmunology 4:1\u20139. https:\/\/doi.org\/10.1080\/2162402X.2015.1047584","journal-title":"Oncoimmunology"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4081\/oncol.2017.326","volume":"11","author":"BS Kalal","year":"2017","unstructured":"Kalal BS, Upadhya D, Pai VR (2017) Chemotherapy resistance mechanisms in advanced skin cancer. Oncol Rev 11:19\u201325. https:\/\/doi.org\/10.4081\/oncol.2017.326","journal-title":"Oncol Rev"},{"key":"11_CR64","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/sj.jid.5701074","volume":"128","author":"M Karbowniczek","year":"2008","unstructured":"Karbowniczek M, Spittle CS, Morrison T et al (2008) mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128:980\u2013987. https:\/\/doi.org\/10.1038\/sj.jid.5701074","journal-title":"J Invest Dermatol"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"JW Kim","year":"2006","unstructured":"Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177\u2013185. https:\/\/doi.org\/10.1016\/j.cmet.2006.02.002","journal-title":"Cell Metab"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/labinvest.2016.142","volume":"97","author":"M Kiuru","year":"2017","unstructured":"Kiuru M, Busam KJ (2017) The NF1 gene in tumor syndromes and melanoma. Pathobiol Focus 97:146\u2013157. https:\/\/doi.org\/10.1038\/labinvest.2016.142","journal-title":"Pathobiol Focus"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"32748","DOI":"10.18632\/oncotarget.4977","volume":"6","author":"A Koch","year":"2015","unstructured":"Koch A, Lang SA, Wild PJ et al (2015) Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget 6:32748\u201332760. https:\/\/doi.org\/10.18632\/oncotarget.4977","journal-title":"Oncotarget"},{"key":"11_CR68","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA et al (2016) Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21:848\u2013854. https:\/\/doi.org\/10.1634\/theoncologist.2015-0522","journal-title":"Oncologist"},{"key":"11_CR69","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-06-3312","volume":"67","author":"SM Kumar","year":"2007","unstructured":"Kumar SM, Yu H, Edwards R et al (2007) Mutant V600E BRAF increases hypoxia inducible factor-1 a expression in melanoma. Cancer Res 67:3177\u20133185. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3312","journal-title":"Cancer Res"},{"key":"11_CR70","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ejca.2010.01.031","volume":"46","author":"S Kuphal","year":"2010","unstructured":"Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK (2010) Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 46:1159\u20131169. https:\/\/doi.org\/10.1016\/j.ejca.2010.01.031","journal-title":"Eur J Cancer"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1878-0261.12050","volume":"11","author":"A Kvist","year":"2017","unstructured":"Kvist A, Lao H, Cirenajwis H et al (2017) NF1 -mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol 11:438\u2013451. https:\/\/doi.org\/10.1002\/1878-0261.12050","journal-title":"Mol Oncol"},{"key":"11_CR72","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-13-0142","volume":"19","author":"LN Kwong","year":"2013","unstructured":"Kwong LN, Davies MA (2013) Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 19:5310\u20135319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0142","journal-title":"Clin Cancer Res"},{"key":"11_CR73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/jclinpath-2015-202885","volume":"68","author":"K Lai","year":"2015","unstructured":"Lai K, Killingsworth MC, Lee CS (2015) Gene of the month: PIK3CA. J Clin Pathol 68:253\u2013257. https:\/\/doi.org\/10.1136\/jclinpath-2015-202885","journal-title":"J Clin Pathol"},{"key":"11_CR74","doi-asserted-by":"publisher","first-page":"20534","DOI":"10.1074\/jbc.M611782200","volume":"282","author":"SC Land","year":"2007","unstructured":"Land SC, Tee AR (2007) Hypoxia-inducible factor 1\u03b1 is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282:20534\u201320543. https:\/\/doi.org\/10.1074\/jbc.M611782200","journal-title":"J Biol Chem"},{"key":"11_CR75","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214\u2013218. https:\/\/doi.org\/10.1038\/nature12213","journal-title":"Nature"},{"key":"11_CR76","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/imt-2016-0022","volume":"8","author":"J Lee","year":"2016","unstructured":"Lee J, Kefford R, Carlino M (2016) PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy 8:733\u2013746. https:\/\/doi.org\/10.2217\/imt-2016-0022","journal-title":"Immunotherapy"},{"key":"11_CR77","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ijo.2018.4287","volume":"52","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R et al (2018) Cutaneous melanoma: from pathogenesis to therapy. Int J Oncol 52:1071\u20131080. https:\/\/doi.org\/10.3892\/ijo.2018.4287","journal-title":"Int J Oncol"},{"key":"11_CR78","doi-asserted-by":"publisher","first-page":"20281","DOI":"10.1074\/jbc.274.29.20281","volume":"274","author":"J Li","year":"2002","unstructured":"Li J, Okino ST, Whitlock JP et al (2002) Regulation of GLUT1 gene transcription by the serine\/threonine kinase Akt1. J Biol Chem 274:20281\u201320286. https:\/\/doi.org\/10.1074\/jbc.274.29.20281","journal-title":"J Biol Chem"},{"key":"11_CR79","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.molcel.2018.01.001","volume":"69","author":"XX Li","year":"2018","unstructured":"Li XX, Wang ZJ, Zheng Y et al (2018) Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol Cell 69:480\u2013492.e7. https:\/\/doi.org\/10.1016\/j.molcel.2018.01.001","journal-title":"Mol Cell"},{"key":"11_CR80","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/jci96113","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM et al (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade\u2013mediated tumor regression. J Clin Invest 128:805\u2013815. https:\/\/doi.org\/10.1172\/jci96113","journal-title":"J Clin Invest"},{"key":"11_CR81","doi-asserted-by":"publisher","unstructured":"Liu T, Jin L, Chen M et al (2019) Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-\u03b1 dependent PDK-1 signaling pathway. Redox Biol:101197. https:\/\/doi.org\/10.1016\/j.redox.2019.101197","DOI":"10.1016\/j.redox.2019.101197"},{"key":"11_CR82","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1253735.The","volume":"346","author":"JA Lo","year":"2014","unstructured":"Lo JA, Fisher DE (2014) The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 346:945\u2013949. https:\/\/doi.org\/10.1126\/science.1253735.The","journal-title":"Science"},{"key":"11_CR83","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231\u2013237. https:\/\/doi.org\/10.1016\/j.coi.2010.01.009","journal-title":"Curr Opin Immunol"},{"key":"11_CR84","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin GA, Viskoohil D, Bollag G et al (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843\u2013849. https:\/\/doi.org\/10.1016\/0092-8674(90)90150-D","journal-title":"Cell"},{"key":"11_CR85","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2012.45.5568","volume":"31","author":"GA Mcarthur","year":"2012","unstructured":"Mcarthur GA, Ribas A (2012) Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 31:499\u2013506. https:\/\/doi.org\/10.1200\/JCO.2012.45.5568","journal-title":"J Clin Oncol"},{"key":"11_CR86","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.18632\/oncotarget.659","volume":"3","author":"JA McCubrey","year":"2015","unstructured":"McCubrey JA, Steelman LS, Chappell WH et al (2015) Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3:1068\u20131111. https:\/\/doi.org\/10.18632\/oncotarget.659","journal-title":"Oncotarget"},{"key":"11_CR87","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/23723556.2014.991610","volume":"2","author":"JL McQuade","year":"2015","unstructured":"McQuade JL, Vashisht Gopal Y (2015) Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition. Mol Cell Oncol 2:2\u20134. https:\/\/doi.org\/10.4161\/23723556.2014.991610","journal-title":"Mol Cell Oncol"},{"key":"11_CR88","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320\u2013328. https:\/\/doi.org\/10.1016\/j.tibs.2011.03.006","journal-title":"Trends Biochem Sci"},{"key":"11_CR89","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.4049\/jimmunol.0903670.AN","volume":"185","author":"JD Mezrich","year":"2010","unstructured":"Mezrich JD, Fechner JH, Zhang X et al (2010) Hydrocarbon receptor can generate regulatory T. J Immunol 185:3190\u20133198. https:\/\/doi.org\/10.4049\/jimmunol.0903670.AN","journal-title":"J Immunol"},{"key":"11_CR90","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jsbmb.2011.07.002.Identification","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR et al (2006) Regression in patients after transfer of gentically engineered lymphocytes. Science 314:126\u2013129. https:\/\/doi.org\/10.1016\/j.jsbmb.2011.07.002.Identification","journal-title":"Science"},{"key":"11_CR91","doi-asserted-by":"publisher","unstructured":"Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxy-genase and tumor-induced tolerance. J Clin Invest 117:1147\u20131154. https:\/\/doi.org\/10.1172\/JCI31178","DOI":"10.1172\/JCI31178"},{"key":"11_CR92","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","volume":"37","author":"DH Munn","year":"2016","unstructured":"Munn DH, Mellor AL, Regents G, Place F (2016) IDO in the tumor microenvironment: inflammation, counter- regulation and tolerance. Trends Immunol 37:193\u2013207. https:\/\/doi.org\/10.1016\/j.it.2016.01.002","journal-title":"Trends Immunol"},{"key":"11_CR93","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.2147\/OTT.S117121","volume":"10","author":"E Mu\u00f1oz-Couselo","year":"2017","unstructured":"Mu\u00f1oz-Couselo E, Adelantado EZ, Ortiz C et al (2017) NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther 10:3941\u20133947. https:\/\/doi.org\/10.2147\/OTT.S117121","journal-title":"Onco Targets Ther"},{"key":"11_CR94","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.4049\/jimmunol.1300772","volume":"191","author":"A Nasi","year":"2013","unstructured":"Nasi A, Fekete T, Krishnamurthy A et al (2013) Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol 191:3090\u20133099. https:\/\/doi.org\/10.4049\/jimmunol.1300772","journal-title":"J Immunol"},{"key":"11_CR95","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/mc.22310","volume":"55","author":"TH Nasti","year":"2016","unstructured":"Nasti TH, Cochran JB, Tsuruta Y et al (2016) A murine model for the development of melanocytic nevi and their progression to melanoma. Mol Carcinog 55:646\u2013658. https:\/\/doi.org\/10.1002\/mc.22310","journal-title":"Mol Carcinog"},{"key":"11_CR96","first-page":"85","volume":"5","author":"LB Naves","year":"2017","unstructured":"Naves LB, Almeida L, Ramakrishna S (2017) Understanding the microenvironment of melanoma cells for the development of target drug delivery systems. Eur Med J 5:85\u201392","journal-title":"Eur Med J"},{"key":"11_CR97","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41594-018-0133-6","volume":"25","author":"C Nemoz","year":"2018","unstructured":"Nemoz C, Ropars V, Frit P et al (2018) XLF and APLF bind Ku80 at two remote sites to ensure DNA repair by non-homologous end joining. Nat Struct Mol Biol 25:971\u2013980. https:\/\/doi.org\/10.1038\/s41594-018-0133-6","journal-title":"Nat Struct Mol Biol"},{"key":"11_CR98","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","volume":"74","author":"MH Nissan","year":"2014","unstructured":"Nissan MH, Pratilas CA, Jones AM et al (2014) Loss of NF1 in Cutaneous Melanoma is associated with RAS activation and MEK dependence. Cancer Res 74:2340\u20132351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2625","journal-title":"Cancer Res"},{"key":"11_CR99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.0105-2896.2009.00879.x","volume":"234","author":"MC Nussenzweig","year":"2010","unstructured":"Nussenzweig MC (2010) Origin and development of dendritic cells. Immunol Rev 234:45\u201354. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00879.x","journal-title":"Immunol Rev"},{"key":"11_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2016.00109","volume":"7","author":"A Ohta","year":"2016","unstructured":"Ohta A (2016) A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 7:1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2016.00109","journal-title":"Front Immunol"},{"key":"11_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00304","volume":"5","author":"A Ohta","year":"2014","unstructured":"Ohta A, Sitkovsky M (2014) Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol 5:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2014.00304","journal-title":"Front Immunol"},{"key":"11_CR102","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00262-012-1389-z","volume":"62","author":"PA Ott","year":"2013","unstructured":"Ott PA, Henry T, Baranda SJ et al (2013) Inhibition of both BRAF and MEK in BRAFV600Emutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 62:811\u2013822. https:\/\/doi.org\/10.1007\/s00262-012-1389-z","journal-title":"Cancer Immunol Immunother"},{"key":"11_CR103","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4065\/mcp.2011.0287","volume":"86","author":"SR Palmer","year":"2011","unstructured":"Palmer SR, Erickson LA, Ichetovkin I et al (2011) Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc 86:981\u2013990. https:\/\/doi.org\/10.4065\/mcp.2011.0287","journal-title":"Mayo Clin Proc"},{"key":"11_CR104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","volume":"3","author":"I Papandreou","year":"2006","unstructured":"Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187\u2013197. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.012","journal-title":"Cell Metab"},{"key":"11_CR105","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"11_CR106","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1158\/2159-8290.CD-13-0440","volume":"43","author":"TJ Parmenter","year":"2014","unstructured":"Parmenter TJ, Kleinschmidt M, Kinross KM et al (2014) Response of BRAF mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 43:1983\u20131987. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0440","journal-title":"Cancer Discov"},{"key":"11_CR107","doi-asserted-by":"publisher","first-page":"106132","DOI":"10.18632\/oncotarget.22190","volume":"8","author":"A Passarelli","year":"2017","unstructured":"Passarelli A, Mannavola F, Stucci LS et al (2017) Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget 8:106132\u2013106142. https:\/\/doi.org\/10.18632\/oncotarget.22190","journal-title":"Oncotarget"},{"key":"11_CR108","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA (2019) Targeting tumor-associated macrophages in Cancer. Trends Immunol 40:310\u2013327. https:\/\/doi.org\/10.1016\/j.it.2019.02.003","journal-title":"Trends Immunol"},{"key":"11_CR109","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P et al (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692. https:\/\/doi.org\/10.1038\/ncomms7692","journal-title":"Nat Commun"},{"key":"11_CR110","doi-asserted-by":"publisher","unstructured":"Payen VL, Porporato PE, Baselet B, Sonveaux P (2016) Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci 73:1333\u20131348. https:\/\/doi.org\/10.1007\/s00018-015-2098-5","DOI":"10.1007\/s00018-015-2098-5"},{"key":"11_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-018-0265-8","volume":"9","author":"ME Picco","year":"2019","unstructured":"Picco ME, Castro MV, Quezada MJ et al (2019) STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1. Cell Biosci 9:1\u201314. https:\/\/doi.org\/10.1186\/s13578-018-0265-8","journal-title":"Cell Biosci"},{"key":"11_CR112","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3892\/or.2015.3910","volume":"33","author":"M Pickarski","year":"2015","unstructured":"Pickarski M, Gleason A, Bednar B, Duong LT (2015) Orally active \u03b1v\u03b23 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep 33:2737\u20132745. https:\/\/doi.org\/10.3892\/or.2015.3910","journal-title":"Oncol Rep"},{"key":"11_CR113","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1080\/15384101.2016.1175258","volume":"15","author":"C Pinheiro","year":"2016","unstructured":"Pinheiro C, Miranda-Gon\u00e7alves V, Longatto-Filho A et al (2016) The metabolic microenvironment of melanomas : prognostic value of MCT1 and MCT4. Cell Cycle 15:1462\u20131470. https:\/\/doi.org\/10.1080\/15384101.2016.1175258","journal-title":"Cell Cycle"},{"key":"11_CR114","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00008390-200212000-00006","volume":"12","author":"PM\u00c3 Pollock","year":"2002","unstructured":"Pollock PM\u00c3, Walker GJ, Glendening JM (2002) PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 12:565\u2013575","journal-title":"Melanoma Res"},{"key":"11_CR115","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Harper UL, Hansen KS et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19\u201320. https:\/\/doi.org\/10.1038\/ng1054","journal-title":"Nat Genet"},{"key":"11_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A (2014) Targeting PI3K\/Akt\/mTOR signaling in Cancer. Front Oncol 4:1\u201311. https:\/\/doi.org\/10.3389\/fonc.2014.00064","journal-title":"Front Oncol"},{"key":"11_CR117","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3978\/j.issn.2305-5839.2015.08.11","volume":"3","author":"M Potrony","year":"2015","unstructured":"Potrony M, Badenas C, Aguilera P et al (2015) Update in genetic susceptibility in melanoma. Ann Transl Med 3:210. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.08.11","journal-title":"Ann Transl Med"},{"key":"11_CR118","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15:290\u2013301. https:\/\/doi.org\/10.1038\/nrc3911","journal-title":"Nat Rev Cancer"},{"key":"11_CR119","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1755-148X.2009.00554.x","volume":"22","author":"A Richmond","year":"2009","unstructured":"Richmond A, Yang J, Su Y (2009) The good and the bad of chemokines\/chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175\u2013186. https:\/\/doi.org\/10.1111\/j.1755-148X.2009.00554.x","journal-title":"Pigment Cell Melanoma Res"},{"key":"11_CR120","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21:1019\u20131027. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2708","journal-title":"Clin Cancer Res"},{"key":"11_CR121","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1158\/0008-5472.CAN-06-0983","volume":"66","author":"EK Rofstad","year":"2006","unstructured":"Rofstad EK, Mathiesen B, Kindem K, Galappathi K (2006) Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 66:6699\u20136707. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0983","journal-title":"Cancer Res"},{"key":"11_CR122","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fimmu.2016.00052","volume":"7","author":"S Romero-Garcia","year":"2016","unstructured":"Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, S\u00e1nchez-Garc\u00eda FJ (2016) Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52. https:\/\/doi.org\/10.3389\/fimmu.2016.00052","journal-title":"Front Immunol"},{"key":"11_CR123","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/0008-5472.CAN-14-2785","volume":"75","author":"M Scortegagna","year":"2015","unstructured":"Scortegagna M, Lau E, Zhang T et al (2015) PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets. Cancer Res 75:1399\u20131412. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2785","journal-title":"Cancer Res"},{"key":"11_CR124","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cmet.2016.10.015","volume":"24","author":"KEN Scott","year":"2016","unstructured":"Scott KEN, Cleveland JL (2016) Lactate wreaks havoc on tumor-infiltrating T and NK cells. Cell Metab 24:649\u2013650. https:\/\/doi.org\/10.1016\/j.cmet.2016.10.015","journal-title":"Cell Metab"},{"key":"11_CR125","doi-asserted-by":"publisher","first-page":"42626","DOI":"10.1074\/jbc.m111.282046","volume":"286","author":"DA Scott","year":"2011","unstructured":"Scott DA, Richardson AD, Filipp FV et al (2011) Comparative metabolic flux profiling of melanoma cell lines. J Biol Chem 286:42626\u201342634. https:\/\/doi.org\/10.1074\/jbc.m111.282046","journal-title":"J Biol Chem"},{"key":"11_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in Cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:1\u201314. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"key":"11_CR127","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","volume":"25","author":"M Sensi","year":"2006","unstructured":"Sensi M, Nicolini G, Petti C et al (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357\u20133364. https:\/\/doi.org\/10.1038\/sj.onc.1209379","journal-title":"Oncogene"},{"key":"11_CR128","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.mayocp.2014.02.002.Latest","volume":"89","author":"DJ Shah","year":"2015","unstructured":"Shah DJ, Dronca RS (2015) Latest advances in chemotherapeutic, targeted and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 89:504\u2013519. https:\/\/doi.org\/10.1016\/j.mayocp.2014.02.002.Latest","journal-title":"Mayo Clin Proc"},{"key":"11_CR129","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"11_CR130","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","volume":"22","author":"MV Sitkovsky","year":"2004","unstructured":"Sitkovsky MV, Lukashev D, Apasov S et al (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia -inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657\u2013682. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104731","journal-title":"Annu Rev Immunol"},{"key":"11_CR131","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.abb.2014.06.030","volume":"563","author":"A Slominski","year":"2014","unstructured":"Slominski A, Kim T-K, Bro\u017cyna AA et al (2014) The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1\u03b1 expression and HIF-dependent attendant pathways. Arch Biochem Biophys 563:79\u201393. https:\/\/doi.org\/10.1016\/j.abb.2014.06.030","journal-title":"Arch Biochem Biophys"},{"key":"11_CR132","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/onc.2016.198","volume":"36","author":"JW Smith","year":"2016","unstructured":"Smith JW, Ratnikov BI, Ronai ZA et al (2016) Metabolic rewiring in melanoma. Oncogene 36:147\u2013157. https:\/\/doi.org\/10.1038\/onc.2016.198","journal-title":"Oncogene"},{"key":"11_CR133","doi-asserted-by":"publisher","first-page":"e33418","DOI":"10.1371\/journal.pone.0033418","volume":"7","author":"P Sonveaux","year":"2012","unstructured":"Sonveaux P, Copetti T, de Saedeleer CJ et al (2012) Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One 7:e33418. https:\/\/doi.org\/10.1371\/journal.pone.0033418","journal-title":"PLoS One"},{"key":"11_CR134","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600\u2013mutant advanced melanoma treated with Vemurafenib. N Engl J Med 366:707\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa1112302","journal-title":"N Engl J Med"},{"key":"11_CR135","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/cji.0b013e3182829903","volume":"36","author":"AA Stewart","year":"2013","unstructured":"Stewart AA, Dudley ME, Nath A et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133\u2013151. https:\/\/doi.org\/10.1097\/cji.0b013e3182829903","journal-title":"J Immunother"},{"key":"11_CR136","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507.MYC","volume":"5","author":"ZE Stine","year":"2016","unstructured":"Stine ZE, Walton ZE, Altman BJ et al (2016) MYC, metabolism, and Cancer. Cancer Discov 5:1024\u20131039. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0507.MYC","journal-title":"Cancer Discov"},{"key":"11_CR137","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1113\/jphysiol.2005.088344","volume":"1","author":"C Stock","year":"2005","unstructured":"Stock C, Gassner B, Hauck CR et al (2005) Migration of human melanoma cells depends on extracellular pH and Na+\/H+ exchange. J Physiol 1:225\u2013238. https:\/\/doi.org\/10.1113\/jphysiol.2005.088344","journal-title":"J Physiol"},{"key":"11_CR138","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1034\/j.1398-9995.1999.00099.x","volume":"54","author":"G Tau","year":"1999","unstructured":"Tau G, Rothman P (1999) Biologic functions of the IFN-\u03b3 receptors. Allergy 54:1233\u20131251. https:\/\/doi.org\/10.1034\/j.1398-9995.1999.00099.x","journal-title":"Allergy"},{"key":"11_CR139","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s11065-015-9294-9.Functional","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u20131696. https:\/\/doi.org\/10.1007\/s11065-015-9294-9.Functional","journal-title":"Cell"},{"key":"11_CR140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jtv.2016.03.002","volume":"26","author":"DJ Tobin","year":"2017","unstructured":"Tobin DJ (2017) Introduction to skin aging. J Tissue Viability 26:37\u201346. https:\/\/doi.org\/10.1016\/j.jtv.2016.03.002","journal-title":"J Tissue Viability"},{"key":"11_CR141","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1586\/1744666X.2014.955851","volume":"10","author":"M Tucci","year":"2014","unstructured":"Tucci M, Stucci S, Passarelli A et al (2014) The immune escape in melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol 10:1395\u20131404. https:\/\/doi.org\/10.1586\/1744666X.2014.955851","journal-title":"Expert Rev Clin Immunol"},{"key":"11_CR142","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00262-014-1553-8","volume":"63","author":"V Umansky","year":"2014","unstructured":"Umansky V, Shevchenko I, Bazhin AV, Utikal J (2014) Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunol Immunother 63:1073\u20131080. https:\/\/doi.org\/10.1007\/s00262-014-1553-8","journal-title":"Cancer Immunol Immunother"},{"key":"11_CR143","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Wagle N, Sucker A et al (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4:94\u2013109. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0617","journal-title":"Cancer Discov"},{"key":"11_CR144","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"J\u00c1F Vara","year":"2004","unstructured":"Vara J\u00c1F, Casado E, de Castro J et\u00a0al (2004) PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev 30:193\u2013204. https:\/\/doi.org\/10.1016\/j.ctrv.2003.07.007","journal-title":"Cancer Treat Rev"},{"key":"11_CR145","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","volume":"23","author":"F Vazquez","year":"2013","unstructured":"Vazquez F, Lim JH, Chim H et al (2013) PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23:287\u2013301. https:\/\/doi.org\/10.1016\/j.ccr.2012.11.020","journal-title":"Cancer Cell"},{"key":"11_CR146","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1101\/gad.187252.112","volume":"26","author":"LCW Vredeveld","year":"2012","unstructured":"Vredeveld LCW, Possik PA, Smit MA et al (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26:1055\u20131069. https:\/\/doi.org\/10.1101\/gad.187252.112","journal-title":"Genes Dev"},{"key":"11_CR147","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.193.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Christina YB, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541\u20132550. https:\/\/doi.org\/10.1084\/jem.193.6.2541","journal-title":"J Exp Med"},{"key":"11_CR148","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","volume":"173","author":"L Wang","year":"2018","unstructured":"Wang L, Leite de Oliveira R, Huijberts S et al (2018) An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell 173:1413\u20131425. https:\/\/doi.org\/10.1016\/j.cell.2018.04.012","journal-title":"Cell"},{"key":"11_CR149","first-page":"13","volume":"7","author":"D Weinstein","year":"2014","unstructured":"Weinstein D, Leininger J, Hamby C, Safai B (2014) Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 7:13\u201324","journal-title":"J Clin Aesthet Dermatol"},{"key":"11_CR150","doi-asserted-by":"publisher","first-page":"S38.e1","DOI":"10.1016\/j.jaad.2011.04.038","volume":"65","author":"HK Weir","year":"2011","unstructured":"Weir HK, Marrett LD, Cokkinides V et al (2011) Melanoma in adolescents and young adults (ages 15\u201339 years): United States, 1999\u20132006. J Am Acad Dermatol 65:S38.e1\u2013S38.e13. https:\/\/doi.org\/10.1016\/j.jaad.2011.04.038","journal-title":"J Am Acad Dermatol"},{"key":"11_CR151","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-016-0165-y","volume":"7","author":"RB Weller","year":"2017","unstructured":"Weller RB, Castellsague X (2017) Skin Cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther 7:5\u201319. https:\/\/doi.org\/10.1007\/s13555-016-0165-y","journal-title":"Dermatol Ther"},{"key":"11_CR152","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Green AC, Olsen CM (2016) The growing burden of invasive melanoma : projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 136:1161\u20131171. https:\/\/doi.org\/10.1016\/j.jid.2016.01.035","journal-title":"J Invest Dermatol"},{"key":"11_CR153","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155\u2013164. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1","journal-title":"Lancet Oncol"},{"key":"11_CR154","first-page":"2871","volume":"36","author":"S Yan","year":"2016","unstructured":"Yan S, Coffing BN, Li Z et al (2016) Diagnostic and prognostic value of ProEx C and GLUT1 in melanocytic lesions. Anticancer Res 36:2871\u20132880","journal-title":"Anticancer Res"},{"key":"11_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00500","volume":"8","author":"EA Zaal","year":"2018","unstructured":"Zaal EA, Berkers CR (2018) The influence of metabolism on drug response in Cancer. Front Oncol 8:1\u201315. https:\/\/doi.org\/10.3389\/fonc.2018.00500","journal-title":"Front Oncol"},{"key":"11_CR156","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","volume":"4","author":"KI Zeller","year":"2003","unstructured":"Zeller KI, Jegga AG, Aronow BJ et al (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4:R69. https:\/\/doi.org\/10.1186\/gb-2003-4-10-r69","journal-title":"Genome Biol"},{"key":"11_CR157","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2006","unstructured":"Zhang W, Liu HT (2006) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9\u201318. https:\/\/doi.org\/10.1038\/sj.cr.7290105","journal-title":"Cell Res"},{"key":"11_CR158","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-1371","volume":"8","author":"M Zhang","year":"2018","unstructured":"Zhang M, Di Martino JS, Bowman RL et al (2018) Adipocyte-derived lipids mediate melanoma progression via FATP proteins. Cancer Discov 8:1006\u20131025. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1371","journal-title":"Cancer Discov"},{"key":"11_CR159","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0002-9440(10)64627-5","volume":"157","author":"X Zhou","year":"2000","unstructured":"Zhou X, Gimm O, Hampel H et al (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123\u20131128. https:\/\/doi.org\/10.1016\/S0002-9440(10)64627-5","journal-title":"Am J Pathol"}],"container-title":["Advances in Experimental Medicine and Biology","Tumor Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-34025-4_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T10:15:20Z","timestamp":1708337720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-34025-4_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030340247","9783030340254"],"references-count":158,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-34025-4_11","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"5 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}